Browsing Centre for Experimental Medicine and Rheumatology (EMR) by Author "Edwards, CJ"
Now showing items 1-4 of 4
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Smolen, JS; Landewe, RBM; Bergstra, SA; Kerschbaumer, A; Sepriano, A; Aletaha, D; Caporali, R; Edwards, CJ; Hyrich, KL; Pope, JE (2023) -
Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjogren's Syndrome
Bowman, SJ; Everett, CC; O'Dwyer, JL; Emery, P; Pitzalis, C; Ng, W-F; Pease, CT; Price, EJ; Sutcliffe, N; Gendi, NST (2017-07) -
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Humby, F; Durez, P; Buch, MH; Lewis, MJ; Rizvi, H; Rivellese, F; Nerviani, A; Giorli, G; Mahto, A; Montecucco, C (2021-01-23)BACKGROUND: Although targeted biological treatments have transformed the outlook for patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is mechanistically still unexplained. Because more ... -
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials
Rivellese, F; Nerviani, A; Giorli, G; Warren, L; Jaworska, E; Bombardieri, M; Lewis, MJ; Humby, F; Pratt, AG; Filer, A (2023-11-01)Background: Despite highly effective targeted therapies for rheumatoid arthritis, about 40% of patients respond poorly, and predictive biomarkers for treatment choices are lacking. We did a biopsy-driven trial to compare ...